References

Goodyear D, et al. Treatment Patterns Among Patients with HAE-C1- INH: Interim Analysis Findings from US and Canada Participants in the EMPOWER Study. J Allergy Clin Immunol 2022; 149(2): Abstract #502.

Johnston D, et al. Long-term Effectiveness and Safety of Lanadelumab in the US and Canada: Findings from the EMPOWER Study. J Allergy Clin Immunol 2022; 149(2): Abstract #495.

Busse P, et al. Impact of Lanadelumab on Patient-Reported Outcomes in Hereditary Angioedema in the US and Canada: Interim Findings from the EMPOWER Study. J Allergy Clin
Immunol 2022; 149(2): Abstract #496.

Lumry W, et al. Lanadelumab Efficacy and Safety After Switching from Androgens: Analysis of the Phase 3 HELP and HELP OLE Studies for Hereditary Angioedema. J Allergy Clin Immunol 2022; 149(2): Abstract #498.

Wedner HJ, et al. Sustained Reductions in Hereditary Angioedema (HAE) Attack Rates Observed over 96 Weeks of Oral Berotralstat Treatment Regardless of Initial Response. J Allergy Clin Immunol 2022; 149(2): Abstract #490.

Aygoren-Pursun E, et al. Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate. J Allergy Clin Immunol 2022; 149(2): Abstract #491.

Gower R, et al. Sustained Improvement Observed in Patient- Reported Quality of Life (QoL) with 96 Weeks of Oral Berotralstat Treatment. J Allergy Clin Immunol 2022; 149(2): Abstract #492.

Fijen L, et al. The Impact on Quality of Life Following Treatment with Plasma Prekallikrein Targeted Oligonucleotide Antisense Therapy in Hereditary Angioedema Patients. J Allergy Clin Immunol 2022; 149(2): Abstract #506.

Bordone L, et al. Pharmacodynamics and Pharmacokinetics of PKK-LRx in Patients with Hereditary Angioedema. J Allergy Clin Immunol 2022; 149(2): Abstract #493.

Cohn D, et al. An Open-label Trial With Plasma Prekallikrein Oligonucleotide Antisense Therapy To Control Angioedema Attacks In Hereditary Angioedema Patients With Normal C1-inhibitor. J Allergy Clin Immunol 2022; 149(2): Abstract #494.

Duckworth E, et al. Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema. J Allergy Clin Immunol 2022; 149(2): Abstract #500.

Audhya U et al. Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema. J Allergy Clin Immunol 2022; 149(2): Abstract #509.

Laney D, et al. Implementation of an Automated Prediction Scoring System to Identify Patients at Possible Increased Risk for Hereditary Angioedema. J Allergy Clin Immunol 2022; 149(2): Abstract #124.

Ishmael F, et al. Can Plasma MicroRNA Expression Patterns Predict Who May Develop Severe Hereditary Angioedema (HAE)? J Allergy Clin Immunol 2022; 149(2): Abstract #670.

Jointly Provided by American Academy of CME and CheckRare CE

Supported by an educational grant from CSl Behring.

Start date: June 15, 2022
End date: June 14, 2023
Estimated time to complete: 0.25 hours

NO LONGER AVAILABLE FOR CREDIT

Activity Description

This accredited CME activity, led by Paula Busse, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American Academy of Allergy, Asthma, & Immunology 2022 (2022 AAAAI) Annual Meeting. Since the Covid-19 pandemic continues to impact travel and the ability of clinicians to attend large conferences, this program was developed to provide a concise means to share the clinically relevant information presented at the meeting with health care professionals who my care for individuals with HAE.

Activity Faculty

Paula Busse, MD
Associate Professor, Medicine, Division of Clinical Immunology
Icahn School of Medicine at Mount Sinai

Target Audience

This activity has been designed to meet the educational needs of physicians specializing in pulmonology, immunology, internal medicine, general practice, and emergency medicine. Other members of the care team may also participate.

After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage people with HAE and its clinical relevance

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educators

Dr. Busse discloses the following relevant financial relationships with ineligible companies to disclose:

• Advisory Board/Consultant: CSL Behring, Kalvista, Biocryst, Takeda, Regeneron, Novartis
• Grant/Research Support: CSL Behring, Kalvista, Biocryst, Takeda, Regeneron, Novartis

Planners for this activity have no relevant financial relationships with any ineligible companies.

This activity will review off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Slides

Transcripts

Hereditary Angioedema (HAE) Research Highlights: 2022 AAAAI Annual Meeting - transcripts